Please login to the form below
13
Revenue 2017Bristol-Myers Squibb
The Top Pharma List rankings are compiled from GlobalData's pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. They have been compiled below into an infographic of Bristol-Myers Squibb's 2013 sales performance.
bluebird bio splits to create new oncology firm 2seventy bio
Its portfolio includes a development and commercialisation deal with Bristol Myers Squibb for Abecma (idecabtagene vicleucel), its B-cell maturation antigen (BCMA)-directed CAR T-cell therapy approved by the Food
BMS reports strong growth as its Q3 results beat predictions
US-based Bristol Myers Squibb (BMS) has announced a 10% increase in revenue in the three months to September, driven by strong demand across all four of its key therapeutic areas.
Bristol Myers Squibb announces data on Zeposia from DAYBREAK study in MS
Bristol Myers Squibb has announced interim results from the phase 3 extension trial DAYBREAK, demonstrating the long-term efficacy and safety profile of Zeposia (ozanimod) in patients with relapsing forms of ... Immunology and Fibrosis Development,
Merck to acquire Acceleron in a deal worth around $11.5bn
The drug is part of a long-standing global collaboration with Celgene, now part of Bristol Myers Squibb (BMS).
Mysterious big pharma company eyes US biotech Acceleron
MSD or Bristol Myers Squibb. ... The drug is part of a long-standing global collaboration with Celgene, now part of Bristol Myers Squibb (BMS).
[ Previous 5 results ] 1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]
Data provided by GlobalData
GlobalData is the premier source of research and consulting solutions for the pharmaceutical and medical device industries. With the combined expertise of more than 600 researchers, market analysts and consultants, we deliver high-quality, accurate and transparent industry insight that helps our clients to achieve growth and increase business value.
To find out more about how our research and consulting solutions can help you, please visit healthcare.globaldata.com
For more details on the data and methodology used to create the Top Pharma Lists, please visit PMLiVE's Top Pharma List - Methodology
Subscribe to our email news alerts
Featured jobs
- Country Manager, Healthcare Communications Agency, Germany
-
Highly competitive salary
- Sanofi halts recruitment for trials assessing MS treatment
- bluebird bio reveals plans to launch two gene therapies
- ONS data reveals significant decrease in COVID-19 antibodies
- AbbVie and Sosei Heptares collaborate in new agreement worth up to $1.2bn
- Eli Lilly to make bebtelovimab commercially available to US states from August
- ONS records a continued fall in UK COVID-19 infections
- Moderna’s Omicron booster receives MHRA approval
- Lack of evidence for AstraZeneca’s COVID-19 vaccine says UK Department of Health
- NHS England outlines measures to boost capacity ahead of substantial winter pressures
- New research shows drug candidate may effectively treat antibiotic-resistant bacteria
- Sanofi and NIHR enrol first patient in immunisation study for RSV in infants
- Engaging KOLs and Gaining Insights in Pharma's New Normal
- AstraZeneca and Daiichi Sankyo receive FDA approval for lung cancer drug
- AbbVie and Sosei Heptares collaborate in new agreement worth up to $1.2bn
- Roche shares new positive Ocrevus data for MS patients
- AstraZeneca and MSD’s breast cancer drug Lynparza receives EC approval
- bluebird bio reveals plans to launch two gene therapies
- NHS App to revolutionise digital health and care with major digital updates by 2023
PMHub
The Difference Collective
Welcome to the Difference Collective – a healthcare communications team of 80+ talented experts who Deliver Differently. We’re purpose-built around...
Latest intelligence
- The communication challenge of helping he next generation to be healthier
- As the pressure on the health service increases the health of the next generation is vital for everyone. How do we show positive attitudes and change behaviour while future proofing...
- Are we losing sight of what the democratisation of healthcare really looks like?
- We have a core responsibility as healthcare communicators to consistently drive for better inclusion, engagement and compliance. What does the ‘democratisation of healthcare’ really look like?...
- How the Royal Society’s EiR programme can help to drive UK innovation
- ...
